Yes, I would be glad to.
Clearly there's a very close connection between research, science innovation, and our market access opportunities. In the case of Korea, there are two things at play. We are a “controlled risk” country in terms of BSE status at the OIE. That controlled risk status, as opposed to “undetermined”, has been very influential in the market access gains we've made across the world, including our work in Korea today.
Canadian officials worked very hard at the OIE in terms of bringing sound science to establish the new ratings around controlled risk, negligible risk, and undetermined risk. Canada was instrumental in achieving the desired results at the OIE, which allowed us then to be classified within that category and has allowed us to trade legally under WTO SPS rules.
In terms of Korea, the second piece is that of course.... As you know, there was a WTO case taken by the Government of Canada against Korea—and we're appreciative of that, by the way. The panel heard all the arguments, both written and oral. About three or four days before the report was to be made public to the parties, Korea agreed to move forward with its rule-making process. Part and parcel of the case, from Canada's perspective, involved a whole lot of scientific work, some of it pulled out of recent research. That was critical in order to put our case together.
We believed we were going to be very successful in that case. The Koreans believed we were going to be very successful in that case.